Scott R. Plotkin

16.1k total citations
216 papers, 7.8k citations indexed

About

Scott R. Plotkin is a scholar working on Neurology, Epidemiology and Genetics. According to data from OpenAlex, Scott R. Plotkin has authored 216 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 149 papers in Neurology, 87 papers in Epidemiology and 53 papers in Genetics. Recurrent topics in Scott R. Plotkin's work include Neurofibromatosis and Schwannoma Cases (135 papers), Meningioma and schwannoma management (83 papers) and Glioma Diagnosis and Treatment (53 papers). Scott R. Plotkin is often cited by papers focused on Neurofibromatosis and Schwannoma Cases (135 papers), Meningioma and schwannoma management (83 papers) and Glioma Diagnosis and Treatment (53 papers). Scott R. Plotkin collaborates with scholars based in United States, Germany and United Kingdom. Scott R. Plotkin's co-authors include Vanessa L. Merker, Anat Stemmer‐Rachamimov, Tracy T. Batchelor, Abba J. Kastin, William A. Banks, Fred G. Barker, Patrick Y. Wen, Rakesh K. Jain, Chris Halpin and Jaishri O. Blakeley and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Scott R. Plotkin

199 papers receiving 7.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scott R. Plotkin United States	48	4.1k	2.6k	1.7k	1.5k	1.3k	216	7.8k
Luca Regli Switzerland	46	3.2k 0.8×	1.6k 0.6×	2.3k 1.4×	2.5k 1.7×	2.4k 1.9×	403	10.1k
Kaoru Kurisu Japan	43	2.6k 0.6×	1.6k 0.6×	2.0k 1.2×	1.4k 0.9×	1.5k 1.1×	474	8.7k
Ulrich Sure Germany	43	4.2k 1.0×	1.1k 0.4×	1.5k 0.9×	1.4k 1.0×	1.1k 0.9×	415	8.4k
Marc Levivier Switzerland	53	4.6k 1.1×	2.4k 0.9×	2.5k 1.5×	1.1k 0.7×	1.5k 1.2×	351	10.0k
Elisabeth J. Rushing United States	51	1.7k 0.4×	1.7k 0.6×	2.6k 1.6×	1.9k 1.3×	1.1k 0.9×	235	7.1k
Jérôme Honnorat France	70	9.7k 2.3×	2.7k 1.0×	2.7k 1.6×	3.3k 2.2×	2.1k 1.7×	449	16.7k
Rafael J. Tamargo United States	57	7.2k 1.7×	2.1k 0.8×	800 0.5×	1.1k 0.8×	2.3k 1.8×	338	12.0k
Juha E. Jääskeläinen Finland	52	5.4k 1.3×	2.8k 1.1×	1.8k 1.1×	1.1k 0.7×	2.1k 1.7×	185	9.8k
Bruce R. Korf United States	52	4.5k 1.1×	1.8k 0.7×	618 0.4×	2.7k 1.8×	1.4k 1.1×	242	11.1k
Monika Warmuth‐Metz Germany	49	2.9k 0.7×	1.5k 0.6×	4.2k 2.5×	1.8k 1.2×	1.4k 1.1×	217	7.8k

Countries citing papers authored by Scott R. Plotkin

Since Specialization

Citations

This map shows the geographic impact of Scott R. Plotkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott R. Plotkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott R. Plotkin more than expected).

Fields of papers citing papers by Scott R. Plotkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott R. Plotkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott R. Plotkin. The network helps show where Scott R. Plotkin may publish in the future.

Co-authorship network of co-authors of Scott R. Plotkin

This figure shows the co-authorship network connecting the top 25 collaborators of Scott R. Plotkin. A scholar is included among the top collaborators of Scott R. Plotkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott R. Plotkin. Scott R. Plotkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wood, Christopher G., Anat Stemmer‐Rachamimov, Daniel J. Lee, et al.. (2025). Increased Hemorrhage During Excision of Bevacizumab‐Treated NF2 ‐Related Vestibular Schwannomas. The Laryngoscope. 135(11). 4355–4363.

Oblinger, Janet L., Roberta L. Beauchamp, Françis Robert, et al.. (2024). Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient models. Neuro-Oncology Advances. 6(1). vdae024–vdae024.

Cannon, Ashley, Kavita Y. Sarin, Andrea Petersen, et al.. (2023). Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials. Clinical Trials. 21(1). 67–72.

Sarin, Kavita Y., Brittney Sell, Matthew A. J. Duncton, et al.. (2023). Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma. Science Translational Medicine. 15(717). eade1844–eade1844. 3 indexed citations

Plotkin, Scott R., Jeffrey C. Allen, Girish Dhall, et al.. (2023). Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro-Oncology. 25(8). 1498–1506. 12 indexed citations

Plotkin, Scott R., Frederick G. Barker, D. Bradley Welling, et al.. (2023). Proton Radiotherapy for Vestibular Schwannomas in Patients with NF2-Related Schwannomatosis: A Case Series. Current Oncology. 30(3). 3473–3483.

Jordan, Justin T., Roberta L. Beauchamp, Alona Muzikansky, et al.. (2023). Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2. Neuro-Oncology Advances. 5(1). vdad041–vdad041. 10 indexed citations

Niendorf, Kristin B., et al.. (2022). Genetic testing to gain diagnostic clarity in neurofibromatosis type 2 and schwannomatosis. American Journal of Medical Genetics Part A. 188(8). 2413–2420. 3 indexed citations

Banerjee, Jineta, Jan M. Friedman, Laura J. Klesse, et al.. (2022). COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis. Genetics in Medicine. 25(2). 100324–100324.

10.

Lassman, Andrew B., Patrick Y. Wen, Martin J. van den Bent, et al.. (2021). A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Clinical Cancer Research. 28(3). 452–460. 40 indexed citations

11.

Gerstner, Elizabeth R., Kyrre E. Emblem, Ken Chang, et al.. (2019). Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clinical Cancer Research. 26(1). 206–212. 40 indexed citations

12.

Plotkin, Scott R., Dan G. Duda, Alona Muzikansky, et al.. (2019). Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. Journal of Clinical Oncology. 37(35). 3446–3454. 74 indexed citations

13.

Vranceanu, Ana‐Maria, Emily L. Zale, Eric A. Macklin, et al.. (2018). Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial. JMIR Research Protocols. 7(10). e11008–e11008. 29 indexed citations

14.

Riklin, Eric, Mojtaba Talaei‐Khoei, Vanessa L. Merker, et al.. (2017). First report of factors associated with satisfaction in patients with neurofibromatosis. American Journal of Medical Genetics Part A. 173(3). 671–677. 9 indexed citations

15.

Zhang, Na, Jie Chen, Gino B. Ferraro, et al.. (2017). Anti-VEGF treatment improves neurological function in tumors of the nervous system. Experimental Neurology. 299(Pt B). 326–333. 16 indexed citations

16.

Tomaso, Emmanuelle di, Matija Snuderl, Walid S. Kamoun, et al.. (2011). Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of “Rebound” Revascularization as Mode of Escape. Cancer Research. 71(1). 19–28. 156 indexed citations

17.

Wong, Hon Kit, Johanna Lahdenranta, Walid S. Kamoun, et al.. (2010). Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors. Cancer Research. 70(9). 3483–3493. 85 indexed citations

18.

Batchelor, Tracy T., Dan G. Duda, Emmanuelle di Tomaso, et al.. (2010). Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology. 28(17). 2817–2823. 406 indexed citations

19.

Lu‐Emerson, Christine & Scott R. Plotkin. (2009). The neurofibromatoses. Part 2: NF2 and schwannomatosis.. PubMed. 6(3). E81–6. 43 indexed citations

20.

Tomaso, Emmanuelle di, et al.. (2008). Angiogenesic profile in sporadic and NF2-related schwannomas. Cancer Research. 68. 4434–4434. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact